Ezetimibe/simvastatin Viso Farmaceutica 10 mg/40 mg tablets EFG

Package Leaflet: Information for the User

Introduction

Package Leaflet: Information for the User

Ezetimibe/Simvastatin Viso Farmacéutica 10 mg/10 mg tablets EFG

Ezetimibe/Simvastatin Viso Farmacéutica 10 mg/20 mg tablets EFG

Ezetimibe/Simvastatin Viso Farmacéutica 10 mg/40 mg tablets EFG

Ezetimibe/Simvastatin Viso Farmacéutica 10 mg/80 mg tablets EFG

Read the entire leaflet carefully before you start taking this medicine, because it contains important information for you.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, since it could harm them.
• If you experience any adverse effects, consult your doctor or pharmacist, even if they are adverse effects not listed in this leaflet. See section 4.

Contents of the leaflet

1. What Ezetimibe/Simvastatin Viso Farmacéutica is and what it is used for
2. What you need to know before taking Ezetimibe/Simvastatin Viso Farmacéutica
3. How to take Ezetimibe/Simvastatin Viso Farmacéutica
4. Possible side effects
5. How to store Ezetimibe/Simvastatin Viso Farmacéutica
6. Contents of the pack and other information

1. What Ezetimibe/Simvastatin Viso Farmaceutica is and what it is used for

This medicine contains the active substances ezetimibe and simvastatin. It is used to reduce blood levels of total cholesterol, "bad" cholesterol (LDL cholesterol), and fatty substances called triglycerides. It also increases levels of "good" cholesterol (HDL cholesterol).

Ezetimibe/simvastatin works to reduce cholesterol in two ways. The active substance ezetimibe reduces the cholesterol absorbed from the digestive tract. The active substance simvastatin, which belongs to the group of "statins", inhibits the production of cholesterol made by the body itself.

Cholesterol is one of the fatty substances found in the bloodstream. Your total cholesterol consists mainly of LDL and HDL cholesterol.

LDL cholesterol is often called "bad" cholesterol because it can build up in the walls of your arteries, forming plaques. Over time, this plaque buildup can lead to narrowing of the arteries. This narrowing can slow down or block blood flow to vital organs such as the heart and brain. This interruption in blood flow may cause a heart attack or stroke.

HDL cholesterol is often called "good" cholesterol because it helps prevent bad cholesterol from building up in the arteries and protects against heart disease.

Triglycerides are another type of fat in your blood that may increase the risk of heart disease.

Ezetimibe/simvastatin is used in patients who cannot control their cholesterol levels with diet alone. While taking this medicine, you must continue to follow a cholesterol-lowering diet.

Ezetimibe/simvastatin is used, together with a cholesterol-lowering diet, if you have:

• high blood cholesterol levels (primary hypercholesterolemia [heterozygous familial and non-familial]) or high blood levels of fatty substances (mixed hyperlipidemia):

• that are not well controlled with a statin alone

• for whom a statin and ezetimibe have previously been used as separate tablets

• a hereditary disease (homozygous familial hypercholesterolemia), which increases cholesterol levels in the blood. You may also receive other treatments.

• heart disease; ezetimibe/simvastatin reduces the risk of heart attack, stroke, surgery to improve blood flow to the heart, or hospitalization due to chest pain.

This medicine does not help you to lose weight.

2. What you need to know before taking Ezetimiba/Simvastatina Viso Farmacéutica

Do not take Ezetimiba/Simvastatina Viso Farmacéutica if:

• you are allergic to ezetimibe (hypersensitive), simvastatin, or any of the other ingredients of this medicine (listed in section 6. Contents of the container and additional information)

• you currently have liver problems

• you are pregnant or breastfeeding

• you are taking medicines containing one or more of the following active substances:

• itraconazole, ketoconazole, posaconazole, or voriconazole (used to treat fungal infections)

• erythromycin, clarithromycin, or telithromycin (used to treat infections)

• HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir (HIV protease inhibitors are used to treat HIV infections)

• boceprevir or telaprevir (used to treat hepatitis C virus infection)

• nefazodone (used to treat depression)

• cobicistat

• gemfibrozil (used to lower cholesterol)

• cyclosporine (used in organ transplant patients)

• danazol (a synthetic hormone used to treat endometriosis, a condition in which the inner lining of the uterus grows outside the uterus)

• you are taking or have taken within the last 7 days a medicine containing fusidic acid (used to treat bacterial infection) taken orally or by injection. The combination of fusidic acid and ezetimibe/simvastatin may cause serious muscle problems (rhabdomyolysis).

Do not take more than 10/40 mg of ezetimibe/simvastatin if you are taking lomitapide (used to treat rare, severe genetic cholesterol disorders).

Consult your doctor if you are unsure whether your medicine is listed above.

Warnings and precautions

Inform your doctor:

• about all your medical conditions, including allergies.
• if you consume large amounts of alcohol or have ever had liver disease. Ezetimibe/Simvastatin may not be suitable for you.
• if you are scheduled for surgery. You may need to stop taking ezetimibe/simvastatin tablets for a short period.
• if you are of Asian descent, as you may require a different dose.
• If you have or have had myasthenia (a disease characterized by generalized muscle weakness that, in some cases, affects the muscles used for breathing) or ocular myasthenia (a disease causing weakness of the eye muscles), as statins may sometimes worsen the condition or trigger the onset of myasthenia (see section 4).

Your doctor will perform a blood test before you start taking ezetimibe/simvastatin and may also do so if you develop symptoms of liver problems while taking this medicine. This is to check how well your liver is functioning.

Your doctor may also want to perform blood tests to monitor your liver function after you start treatment with ezetimibe/simvastatin.

While taking this medicine, your doctor will monitor you for diabetes or risk of developing diabetes. This risk increases if you have high levels of sugar and fats in the blood, are overweight, or have high blood pressure.

Talk to your doctor if you have a severe lung disease.

The combined use of ezetimibe/simvastatin and fibrates (certain cholesterol-lowering medicines) should be avoided, as the combination has not been studied.

Contact your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness. This is because, rarely, muscle problems can be serious, including muscle breakdown leading to kidney damage; and very rarely, deaths have occurred.

The risk of muscle breakdown is higher with higher doses of ezetimibe/simvastatin, especially the 10/80 mg dose. The risk of muscle breakdown is also higher in certain patients. Inform your doctor in the following situations:

• if you have kidney problems
• if you have thyroid problems
• if you are over 65 years old
• if you are female
• if you have ever had muscle problems during treatment with cholesterol-lowering medicines called “statins” (such as simvastatin, atorvastatin, and rosuvastatin) or fibrates (such as gemfibrozil or bezafibrate)
• if you or your close family members have an inherited muscle disorder

Also inform your doctor or pharmacist if you experience persistent muscle weakness. Additional tests or treatments may be needed to diagnose and manage this condition.

Children and adolescents

• Ezetimibe/simvastatin is not recommended for children under 10 years of age.

Other medicines and Ezetimiba/Simvastatina Viso Farmacéutica

Tell your doctor if you are taking, have recently taken, or might need to take any other medicine containing any of the following active substances. Taking ezetimibe/simvastatin with any of the following medicines may increase the risk of muscle problems (some of these are already listed in the section above “Do not take Ezetimiba/Simvastatina Viso Farmacéutica if”).

• if you need to take oral fusidic acid to treat a bacterial infection, you will temporarily need to stop using this medicine. Your doctor will advise you when you can restart ezetimibe/simvastatin treatment. Using ezetimibe/simvastatin with fusidic acid may rarely cause muscle weakness, tenderness, or pain (rhabdomyolysis). For more information on rhabdomyolysis, see section 4.

• cyclosporine (often used in transplant patients)

• danazol (a synthetic hormone used to treat endometriosis, a condition in which the inner lining of the uterus grows outside the uterus)

• medicines containing active substances such as itraconazole, ketoconazole, fluconazole, posaconazole, or voriconazole (used to treat fungal infections)

• fibrates containing active substances such as gemfibrozil and bezafibrate (used to lower cholesterol)

• erythromycin, clarithromycin, or telithromycin (used to treat bacterial infections)

• HIV protease inhibitors such as indinavir, nelfinavir, ritonavir, and saquinavir (used to treat AIDS)

• hepatitis C antivirals such as boceprevir, telaprevir, elbasvir, or grazoprevir (used to treat hepatitis C virus infection)

• nefazodone (used to treat depression)

• medicines containing the active substance cobicistat

• amiodarone (used to treat irregular heart rhythm)

• verapamil, diltiazem, or amlodipine (used to treat high blood pressure, chest pain associated with heart disease, or other heart conditions)

• lomitapide (used to treat rare, severe genetic cholesterol disorders)

• daptomycin (a medicine used to treat complicated skin and skin structure infections and bacteremia). Adverse effects affecting muscles may be increased when this medicine is taken during simvastatin treatment (e.g., Ezetimiba/Simvastatina Viso Farmacéutica). Your doctor may decide that you should temporarily stop taking Ezetimiba/Simvastatina

• high doses (1 gram or more per day) of niacin or nicotinic acid (also used to lower cholesterol)

• colchicine (used to treat gout)

• ribociclib (used to treat breast cancer)

• palbociclib (used to treat breast cancer)

As well as the medicines listed above, inform your doctor or pharmacist if you are taking or have recently taken any other medicines, including those obtained without a prescription. In particular, inform your doctor if you are taking any of the following:

• medicines containing active substances to prevent blood clots, such as warfarin, phenindione, phenprocoumon, or acenocoumarol (anticoagulants)
• colestyramine (also used to lower cholesterol), as it affects how ezetimibe/simvastatin works
• fenofibrate (also used to lower cholesterol)
• rifampicin (used to treat tuberculosis)
• ticagrelor (an antiplatelet medicine)

You should also inform any doctor prescribing a new medicine that you are taking ezetimibe/simvastatin.

Taking Ezetimiba/Simvastatina Viso Farmacéutica with food and drink

Grapefruit juice contains one or more components that interfere with the metabolism of certain medicines, including ezetimibe/simvastatin. Consumption of grapefruit juice should be avoided, as it may increase the risk of muscle problems.

Pregnancy and breastfeeding

Do not take this medicine if you are pregnant, trying to become pregnant, or think you may be pregnant. If you become pregnant while taking ezetimibe/simvastatin, stop taking it immediately and inform your doctor. Do not take ezetimibe/simvastatin while breastfeeding, as it is unknown whether this medicine passes into breast milk.

Consult your doctor or pharmacist before using any medicine.

Driving and using machines

Ezetimibe/simvastatin is not expected to affect your ability to drive or use machines. However, bear in mind that some people may experience dizziness after taking ezetimibe/simvastatin.

Ezetimiba/Simvastatina Viso Farmacéutica contains lactose

This medicine contains lactose. If your doctor has informed you that you have an intolerance to certain sugars, consult with him before taking this medicine.

Ezetimiba/Simvastatina Viso Farmacéutica contains sodium

This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.

3. How to take Ezetimiba/Simvastatina Viso Farmaceutica

Your doctor will determine the appropriate tablet strength for you, depending on your current treatment and individual risk situation.

The tablets do not have a score line and must not be divided.

Always follow your doctor's instructions for taking this medicine exactly. If in doubt, consult your doctor or pharmacist again.

• Before starting ezetimiba/simvastatina, you should already be following a cholesterol-lowering diet.
• You must continue this cholesterol-lowering diet while taking ezetimiba/simvastatina.

Adults: The dose is 1 tablet of ezetimiba/simvastatina once daily by mouth.

Use in adolescents (10 to 17 years of age): The dose is 1 tablet of ezetimiba/simvastatina once daily by mouth (the maximum dose should not exceed 10 mg/40 mg once daily).

The ezetimiba/simvastatina 10 mg/80 mg dose is only recommended for adult patients with very high cholesterol levels and a high risk of heart disease complications who have not achieved their treatment goal with lower doses.

Take ezetimiba/simvastatina at night. It may be taken with or without food.

If your doctor has prescribed ezetimiba/simvastatina together with another cholesterol-lowering medicine containing the active substance colestyramine or any other bile acid sequestrant, you must take ezetimiba/simvastatina at least 2 hours before or 4 hours after taking the bile acid sequestrant.

If you take more Ezetimiba/Simvastatina Viso Farmaceutica than you should

• In case of overdose or accidental ingestion, contact the Toxicology Information Service. Telephone: 91 562 04 20, or consult your doctor or pharmacist.

If you forget to take Ezetimiba/Simvastatina Viso Farmaceutica

• Do not take a double dose to make up for missed doses. Take your usual amount of Ezetimiba/Simvastatina Viso Farmaceutica at the usual time.

If you stop taking Ezetimiba/Simvastatina Viso Farmaceutica

• Talk to your doctor or pharmacist, as your cholesterol levels may rise again.

If you have any further questions about the use of this product, ask your doctor or pharmacist.

4. Possible adverse effects

Like all medicines, this medicine can cause adverse effects, although not everyone gets them (see section 2. What you need to know before you start taking Ezetimibe/Simvastatin Viso Farmaceutica).

The following frequent adverse effects have been reported (may affect up to 1 in 10 people):

• muscle pain
• increases in blood laboratory tests of liver function (transaminases) and/or muscle function (CK)

The following uncommon adverse effects have been reported (may affect up to 1 in 100 people):

• elevated liver function in blood tests; elevated blood uric acid levels; prolonged blood clotting time; protein in urine; weight decrease
• dizziness; headache; tingling sensation
• abdominal pain; indigestion; flatulence; nausea; vomiting; abdominal distension; diarrhea; dry mouth; heartburn
• rash; itching; urticaria
• joint pain; muscle pain, tenderness, weakness, or spasms; neck pain; pain in arms and legs; back pain
• unusual tiredness or weakness; feeling tired; chest pain; swelling, especially of the hands and feet
• sleep disorders; difficulty sleeping

Additionally, the following adverse effects have been reported in people taking ezetimibe/simvastatin or medicines containing the active substances ezetimibe or simvastatin:

• low red blood cell count (anemia), reduced blood cell count, which may cause bruising/bleeding (thrombocytopenia)
• numbness or weakness of arms and legs; memory impairment, memory loss, confusion
• respiratory problems including persistent cough and/or difficulty breathing or fever
• constipation
• inflammation of the pancreas, often with severe abdominal pain
• liver inflammation with the following symptoms: yellowing of the skin and eyes, itching, dark urine or pale stools, feeling tired or weak, loss of appetite; liver failure; gallstones or inflammation of the gallbladder (which may cause abdominal pain, nausea, vomiting)
• hair loss; red, raised rash, sometimes with target-like lesions (erythema multiforme)
• blurred vision and vision loss (may affect up to 1 in 1,000 people)
• skin rash or mouth ulcers (lichenoid eruption) (may affect up to 1 in 10,000 people)
• hypersensitivity reaction which may include: hypersensitivity (allergic reactions including swelling of the face, lips, tongue and/or throat, which may cause difficulty breathing or swallowing and requires immediate treatment (angioedema), joint pain or inflammation, inflammation of blood vessels, atypical bruising, skin rashes and swelling, urticaria, skin sensitivity to sunlight, fever, hot flushes, difficulty breathing and general malaise, pseudolupus syndrome (including skin rash, joint disorders and effects on white blood cells)). A very rare severe allergic reaction (may affect up to 1 in 10,000 people) may occur, causing difficulty breathing or dizziness, and requires immediate treatment (anaphylaxis).
• muscle pain, tenderness, weakness, or cramps; muscle failure; muscle rupture (may affect up to 1 in 10,000 people); tendon problems, sometimes complicated by tendon rupture
• gynaecomastia (enlargement of breasts in men) (may affect up to 1 in 10,000 people)
• decreased appetite
• hot flushes; high blood pressure
• pain
• erectile dysfunction
• depression
• changes in certain blood tests of liver function

The following additional adverse events have been reported with some statins:

• sleep disorders, including nightmares
• sexual dysfunction
• diabetes. This is more likely if you have high levels of blood sugar and fats, are overweight, and have high blood pressure. Your doctor will monitor you while you are taking this medicine
• persistent muscle pain, tenderness, or weakness, which may not resolve after stopping treatment with ezetimibe/simvastatin (frequency not known)
• Myasthenia gravis (a condition causing generalized muscle weakness which, in some cases, affects the muscles used for breathing)
• Ocular myasthenia (a condition causing weakness of the eye muscles)

Consult your doctor if you experience worsening weakness in arms or legs after periods of activity, double vision or drooping eyelids, difficulty swallowing, or difficulty breathing.

Contact your doctor immediately if you experience unexplained muscle pain, tenderness, or weakness. This is because, in rare cases, muscle problems can be serious, including muscle breakdown leading to kidney damage; and very rarely, deaths have occurred.

Reporting of adverse effects:

If you experience any adverse effect, talk to your doctor, pharmacist, or nurse, even if it is a possible adverse effect not listed in this leaflet. You can also report them directly via the Spanish Pharmacovigilance System for Human Medicines:

https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.

5. Storage of Ezetimibe/Simvastatin Viso Farmaceutica

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date stated on the carton or bottle after EXP. The expiry date refers to the last day of the month indicated.

Do not store above 25 °C.

Blister packs: keep the blister in the outer packaging to protect it from moisture.

Bottles: keep the bottle tightly closed and store it in the outer packaging to protect it from moisture.

Medicines must not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE collection point at your pharmacy. If you are unsure, ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.

6. Contents of the pack and other information

Composition of Ezetimiba/Simvastatina Viso Farmacéutica

The active substances are ezetimibe and simvastatin. Each tablet contains 10 mg of ezetimibe and 10 mg, 20 mg, 40 mg or 80 mg of simvastatin.

The other components are: lactose monohydrate, microcrystalline cellulose (E 460), hypromellose, sodium croscarmellose (E 468), propyl gallate (E 310), butylated hydroxyanisole (E 320), citric acid monohydrate (E 330), sodium lauryl sulfate, magnesium stearate (E 470b).

See also section 2 “What you need to know before taking Ezetimiba/Simvastatina Viso Farmacéutica”.

Appearance of Ezetimiba/Simvastatina Viso Farmacéutica and contents of the pack

10 mg/10 mg:

Uncoated, capsule-shaped tablets, white to off-white in colour, with “G” engraved on one side and “321” on the other, approximately 8.5 mm long and 4.25 mm wide.

10 mg/20 mg:

Uncoated, capsule-shaped tablets, white to off-white in colour, with “G” engraved on one side and “322” on the other, approximately 10.7 mm long and 5.3 mm wide.

10 mg/40 mg:

Uncoated, capsule-shaped tablets, white to off-white in colour, with “G” engraved on one side and “323” on the other, approximately 14.0 mm long and 6.0 mm wide.

10 mg/80 mg:

Uncoated, capsule-shaped tablets, white to off-white in colour, with “G” engraved on one side and “324” on the other, approximately 17.5 mm long and 7.5 mm wide.

Ezetimiba/Simvastatina Viso Farmacéutica 10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mg are available in PVC-Aluminium-OPA / Aluminium blisters of 7, 10, 14, 28, 30, 49, 50, 56, 84, 90, 98 tablets, multiple packs containing 98 (2 packs of 49), 100, 196, 300 or 392 tablets, and HDPE bottles of 90 tablets (only Ezetimiba/Simvastatina Viso Farmacéutica 10 mg/40 mg). Tablets packed in HDPE bottles include a desiccant to protect the tablets from moisture. The desiccant must not be swallowed.

Only certain pack sizes may be marketed.

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Glenmark Arzneimittel GmbH
Industriestr. 31
82194 Gröbenzell
Germany

Manufacturer:

Glenmark Pharmaceuticals s.r.o.
Fibichova 143
566 17 Vysoké Mýto
Czech Republic

Pharmadox Healthcare Ltd
KW20A Kordin Industrial Park
Paola PLA3000
Malta

For further information about this medicinal product, please contact the local representative of the Marketing Authorization Holder:

Glenmark Farmacéutica, S.L.U.
C/ Retama 7, 7th floor
28045 Madrid
Spain

This medicinal product is authorized in the European Economic Area member states under the following names:

Netherlands: Ezetimibe/Simvastatine Glenmark 10 mg/10 mg tabletten
Ezetimibe/Simvastatine Glenmark 10 mg/20 mg tabletten
Ezetimibe/Simvastatine Glenmark 10 mg/40 mg tabletten
Ezetimibe/Simvastatine Glenmark 10 mg/80 mg tabletten

Germany: Ezetimibe/Simvastatine Glenmark 10 mg/10 mg tabletten
Ezetimibe/Simvastatine Glenmark 10 mg/20 mg tabletten
Ezetimibe/Simvastatine Glenmark 10 mg/40 mg tabletten
Ezetimibe/Simvastatine Glenmark 10 mg/80 mg tabletten

Czech Republic: Glezisim

Slovakia: Glezisim 10 mg/10 mg tablety
Glezisim 10 mg/20 mg tablety
Glezisim 10 mg/40 mg tablety
Glezisim 10 mg/80 mg tablety

Norway: Ezetimib/Simvastatin Glenmark 10 mg/20 mg tabletter
Ezetimib/Simvastatin Glenmark 10 mg/40 mg tabletter

Spain: Ezetimiba/Simvastatina Viso Farmacéutica 10 mg/20 mg comprimidos EFG
Ezetimiba/Simvastatina Viso Farmacéutica 10 mg/40 mg comprimidos EFG

Date of latest revision of this leaflet: April 2026.

Detailed information on this medicinal product is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS): http://www.aemps.gob.es/